Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Tag Archive for: LNA
Antisense drug developer Secarna Pharmaceuticals and CNS expert SciNeuro Pharmaceuticals have inked an R&D and licence option contract for CNS diseases.